Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 8.49 CHF 5.47% Market Closed
Market Cap: 165.2m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Newron Pharmaceuticals SpA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Newron Pharmaceuticals SpA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Newron Pharmaceuticals SpA
SIX:NWRN
Cash from Financing Activities
€8.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Cash from Financing Activities
-€544.4m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Pierrel SpA
MIL:PRL
Cash from Financing Activities
€6.2m
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
N/A
Friulchem SpA
MIL:FCM
Cash from Financing Activities
€731.6k
CAGR 3-Years
-24%
CAGR 5-Years
122%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Cash from Financing Activities
-€3.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Newron Pharmaceuticals SpA
Glance View

Market Cap
161.7m CHF
Industry
Pharmaceuticals

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

NWRN Intrinsic Value
68.34 CHF
Undervaluation 88%
Intrinsic Value
Price

See Also

What is Newron Pharmaceuticals SpA's Cash from Financing Activities?
Cash from Financing Activities
8.3m EUR

Based on the financial report for Jun 30, 2024, Newron Pharmaceuticals SpA's Cash from Financing Activities amounts to 8.3m EUR.

Back to Top